EG STADA

What EG STADA does

EG STADA (legal entity: EG S.p.A.) is the Italian operating subsidiary of STADA Arzneimittel AG, a publicly listed German pharmaceutical group headquartered in Bad Vilbel. Founded around 1998, EG STADA is headquartered in Milan at Via Pavia n. 6 and operates under the direction and coordination of its parent group. The company produces and distributes three product categories in Italy: generic/equivalent drugs (Farmaci Equivalenti) offering the same active ingredients as branded reference medications at lower cost; Consumer Healthcare products including dermatological (Nizoral, Hirudoid, Lenirit, Eurax), respiratory (Lisomucil, Lisonatural), digestive (Lactease, GlutoSin, Daosin), and wellness brands; and Biosimilars & Specialty medicines spanning oncology, autoimmune, and emerging neurology therapeutic areas. The proprietary technology is conventional pharmaceutical manufacturing and formulation, not software or platform technology.

EG STADA's go-to-market is built on Italy's pharmacy distribution channel, supported by a dedicated field sales force (Informatori Scientifici del Farmaco) targeting physicians and pharmacists. The company maintains a reserved online portal for healthcare professionals, conducts pharmacist continuing education programs (30+ courses since 2023), and operates community health initiatives including the Tour della Salute mobile health program (65,000+ free consultations since 2018) and the Insieme in Salute phygital patient education platform. Pricing is regulated through Italy's SSN reimbursement framework for prescription medicines and standard retail pricing for OTC products; specific pricing is not publicly disclosed.

Revenue mechanics flow through pharmacy dispensing of prescription generics (reimbursed) and OTC consumer healthcare products (cash-pay retail), with the Specialty/Biosimilars segment driving the highest growth — STADA Group's Specialty segment exceeded €1 billion in 2025, supported by 17% biosimilars growth. EG STADA Italy-specific revenue is not separately disclosed; STADA Group reported €4.3 billion in adjusted 2025 revenues. The customer base is fragmented across the Italian population, pharmacy retailers, and prescribing physicians, with no concentration in a small number of institutional buyers. Beyond product distribution, EG STADA conducts the annual STADA Health Report (15+ country European health perception survey since 2014) and partnerships with Italian scientific societies, Federfarma Lombardia, Banco Farmaceutico, and Cittadinanzattiva to reinforce its 'Trusted Partner' positioning in Italian healthcare.

Name

EG STADA

Legal name

EG S.p.A.

Website

https://egstada.it

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

EG STADA is the Italian subsidiary of STADA Arzneimittel AG, producing and distributing generic drugs, consumer healthcare products, and biosimilars in Italy primarily through the national pharmacy network, serving patients, pharmacists, and healthcare professionals.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Erythropoietin (EPO) Biosimilars (HLAIAFAC)

Keywords

• Generic pharmaceuticals
• Consumer healthcare products
• Biosimilar medicines
• OTC medications
• Pharmacy distribution

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic Pharmaceuticals (Farmaci Equivalenti): Generic drugs containing the same active ingredient in the same quantity as branded reference drugs, providing equivalent efficacy and safety at lower cost. This is the historical core business of EG STADA.
2. Consumer Healthcare: Over-the-counter products for wellness, prevention, and everyday health needs. Includes brands like Nizoral, Venoruton, Hirudoid, and others for conditions like hair care, venous circulation, and dermatological issues.
3. Biosimilars and Specialty Medicines: Biosimilar products offering therapeutic alternatives for biological medicines, and specialty pharmaceuticals including oncology generics and innovative therapies in areas like neurology. The Specialty segment exceeded €1 billion in revenues in 2025.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

EG STADA produces and distributes a portfolio of generic pharmaceuticals (farmaci equivalenti), over-the-counter consumer healthcare products, and biosimilar/specialty medicines through Italian pharmacies. The company operates as the Italian subsidiary of STADA ARZNEIMITTEL AG, supplying therapeutic alternatives in dermatology, venous care, respiratory health, digestive health, and biosimilars across a dedicated pharmacy channel.

Product overview

EG STADA operates as a pharmaceutical company with a three-pillar product strategy: Generic Drugs (Farmaci Equivalenti), Consumer Healthcare, and Biosimilars & Specialty medications. The company offers an extensive portfolio of branded products including dermatological treatments (Nizoral, Hirudoid, Lenirit), respiratory products (Lisomucil, Lisonatural), digestive health solutions (Lactease, GlutoSin, Daosin), and specialty medications. Beyond product sales, EG STADA conducts the annual STADA Health Report research initiative and operates public health programs like Tour della Salute and Insieme in Salute patient education platform.

Differentiator

Problem solved

Functional benefit

Brands

• Nizoral: Anti-dandruff and antifungal shampoo brand, including Nizoral Care line (shampoo and conditioner for oily scalp)
• Venoruton
• Hirudoid
• Duofilm
• Lenirit
• Eurax
• Cerumol
• Hedrin
• Lisomucil
• Lisonatural
• Ketodol
• Simecrin
• Zolemer
• Daosin
• Glutosin
• Lactease
• Ergovis
• Sedatol
• Reidrax

Products and services

• Farmaci Equivalenti (Generic Drugs) Generic/equivalent drugs that contain the same active ingredient in the same quantity as branded medications, providing effective and safe therapeutic options at lower costs. Sold through Italian pharmacies.
• Consumer Healthcare Over-the-counter health products including dermatology, respiratory, digestive, and wellness solutions for daily health management, distributed through pharmacies.
• Biosimilari e Farmaci Specialistici (Biosimilars & Specialty) Biological drugs and specialty medications including biosimilars for oncology, autoimmune, and other complex conditions, offering advanced therapeutic options. The Specialty segment exceeded €1 billion in revenues in 2025.
• Nizoral / Nizoral Care
• Venoruton
• Hirudoid
• Duofilm
• Lenirit
• Eurax
• Cerumol
• Hedrin
• Lisomucil Mucolitico
• Lisonatural
• Ketodol
• Simecrin
• Zolemer
• Daosin
• GlutoSin
• Lactease
• Ergovis
• Sedatol
• Reidrax

Quantifiable outcome

• 65,000+ free medical consultations provided through Tour della Salute initiative
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core and minor.

• Federfarma LombardiacoreStrategic or Co-development PartnerFederfarma Lombardia represents pharmacy owners in the Lombardy region. EG STADA supports the Progetto Mimosa Lombardia initiative, building a stable network between pharmacies, healthcare professionals, institutions, and associations to develop concrete prevention, listening, and support models for women victims of violence.
• Banco Farmaceutico - Fondazione ETScoreStrategic or Co-development PartnerBanco Farmaceutico organizes the annual Giornate di Raccolta del Farmaco (Medicine Collection Days), a solidarity campaign supporting people in difficulty accessing healthcare. EG STADA participates as volunteers and supporters, contributing to collection efforts across 6,000+ participating pharmacies supporting 2,000+ charitable organizations.
• Fondazione Francesca Rava - NPH Italia ETSminorStrategic or Co-development PartnerFoundation dedicated to supporting children in need in Italy and abroad. EG STADA supports the 'In Farmacia per i Bambini' initiative addressing healthcare poverty among minors, complementing the Banco Farmaceutico activities.
• ASC - Attività Sportive ConfederatecoreStrategic or Co-development PartnerASC is the promoter of the Tour della Salute initiative, an Italian mobile health prevention program. EG STADA is the main sponsor (trusted partner) of this project that provides free medical consultations and health screenings across Italian cities, having conducted over 65,000 consultations since 2018.
• Scientific Societies (ADI, ADOI, SIPREC, CreI, FNOVI, SIOCMF, FIP)coreStrategic or Co-development PartnerMultiple Italian scientific societies collaborate with Tour della Salute: Italian Dietetic and Clinical Nutrition Association (ADI), Italian Hospital Dermatologists (ADOI), Italian Cardiovascular Prevention Society (SIPREC), Italian College of Rheumatologists (CreI), National Federation of Veterinary Doctors (FNOVI), Italian Society of Odontostomatology (SIOCMF), and Italian Psychologists Federation (FIP).
• CittadinanzattivaminorStrategic or Co-development PartnerCittadinanzattiva is an Italian civic participation organization. EG STADA supports the 'IoEquivalgo' multi-year information and awareness project on generic medicines, launched in 2016, providing citizens and healthcare professionals with clear tools to make informed therapeutic choices.
• Cosmofarma ExhibitioncoreGTM or Marketing PartnerCosmofarma is Italy's major pharmacy and health industry exhibition. EG STADA participates annually with a booth (Hall 29, Stand D35-E36) to engage with pharmacists, present products, and discuss industry topics like prevention, sustainability, and the evolving role of pharmacy.
• LIMPE-DISMOVminorStrategic or Co-development PartnerLIMPE-DISMOV is an Italian neurological congress focused on movement disorders. EG STADA made its official debut at the 2026 edition in Rimini, marking entry into a new therapeutic area (neurology) with a new therapeutic solution.

Scale indicators8 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Doc Generici: Italian-focused generic pharmaceutical company and one of the largest domestic generic players. Direct competitor in Italian generics, distributed through the same pharmacy channel, competing on price for the same therapeutically equivalent molecules.
• Krka (Italian operations): Slovenian-headquartered generic pharmaceutical manufacturer with strong presence in Italy. Competes with EG STADA across generic pharmaceutical categories distributed through Italian pharmacies, leveraging Central European manufacturing scale for cost-competitive generics.
• Aurobindo Pharma Italia: India-headquartered global generic manufacturer with significant Italian operations. Competes with EG STADA in Italy across generic pharmaceuticals, leveraging lower-cost manufacturing to compete on price in the Italian pharmacy channel.
• Viatris (Mylan Italia): Formed from Mylan-Pfizer Upjohn merger, Viatris is a global generics powerhouse with strong Italian presence. Competes head-to-head with EG STADA in generic pharmaceuticals distributed through Italian pharmacies, targeting the same patient affordability and therapeutic continuity value propositions.
• Teva Pharmaceutical Industries (Teva Italia): Global leader in generic pharmaceuticals with a major Italian operation. Directly competes with EG STADA across the same generic and biosimilar categories distributed through Italian pharmacies, with overlapping target customers (pharmacists, physicians) and a similar three-segment portfolio model.
• Sandoz (Sandoz Italia): One of the world's largest generic and biosimilar manufacturers and a Novartis spin-off. Direct competitor to EG STADA in Italian generics and biosimilars, with comparable pharmacy-channel distribution and specialty/biosimilar growth strategy.
• Zentiva: European-focused generic pharmaceutical company with pan-European operations including Italy. Direct competitor in generic drugs distributed through Italian pharmacies, with similar portfolio breadth across therapeutic categories.

Others

• Menarini Group: One of Italy's largest pharmaceutical companies with broad portfolio across prescription, consumer healthcare, and diagnostics. Overlaps with EG STADA in Italian consumer healthcare categories and pharmacy distribution, though Menarini is a much broader, Italy-based incumbent.

Broad incumbents

• Chiesi Farmaceutici: Major Italian pharmaceutical company with operations across specialty, consumer healthcare, and rare diseases. Overlaps with EG STADA in respiratory (Lisomucil competes with Chiesi respiratory products), consumer healthcare, and specialty therapeutics, though Chiesi is much larger and more diversified.
• Angelini Pharma: Italian private pharmaceutical group with broad consumer healthcare, prescription, and specialty operations. Overlaps with EG STADA in Italian consumer healthcare categories (dermatology, OTC) and pharmacy distribution, though Angelini is a broader and more diversified Italian incumbent.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eg-italia-gruppo-stada
• Facebookfacebook.com/egitaliagruppostada

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EG STADA